



**Canadian Arthritis Network
International Partnership Initiative**

**International Research & Training Program
LABORATORY/CLINIC PROFILE**

Contact information of the principal investigator

Name:	Dr. Janet E. Pope
Dept and Institution:	Medicine/Rheumatology; St. Joseph's Health Centre
Complete mailing address:	St. Joseph's Health Centre 268 Grosvenor St. London, Ontario N6A 4V2
Phone:	519-646-6332
Email:	janet.pope@sjhc.london.on.ca

Please indicate if you are member or affiliate of one or more of the following International Partnership Initiative organizations:

- AO Foundation – Biotechnology Advisory Board, Switzerland
- Arthritis Foundation, USA
- Arthritis Research Campaign, UK
- Canadian Arthritis Network, Canada
- Japan Society for the Promotion of Science, Japan
- Nuffield Foundation Oliver Bird Rheumatism Program, UK

International Research & Training Program Opportunity

Please indicate which of the following international opportunities would be available at your laboratory/clinic.

- Training Elective Rotation
- Research Mini-sabbatical
- Industry Training Rotation



The International Research & Training Program will be available for trainee elective rotations and investigator mini-sabbaticals that commence on or before March 31, 2009. If you have any preferences regarding the dates when you can host an international trainee or investigator, please indicate this below.

Visit Length (please indicate start and end dates if known):	Not in the month of August.
---	-----------------------------

Please provide ten key words and a brief description of the research currently being conducted in your laboratory/clinic, including descriptions of any specialized equipment, methods or technologies employed at your facility.

10 key words

<ol style="list-style-type: none">1. Scleroderma2. Lupus3. Rheumatoid arthritis4. Osteoarthritis5. Gout6. Raynaud's phenomenon7. Randomized controlled drug trials8. Registries (scleroderma, lupus)9. Questionnaires (SLICC, SLAM, SLEDAI, HAQ, SF-36)10. Disease activity monitoring

Brief description (up to ½ page)

<p>I have a large research staff of full and part-time nurses and assistants who are usually conducting about 10 to 15 clinical studies at any given time. I am the principal investigator in two new drug trials "A randomized, placebo-controlled trial of St. John's Wort (a natural herbal product) in the treatment of Raynaud's Phenomenon (RP)" and "A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma", as well as a co-investigator in several Canadian Institutes of Health Research sponsored studies. I am also the site principal investigator in many industry-sponsored drug trials including studies of Humira and Rituximab in rheumatoid arthritis and Bosentan in the treatment of digital ulcers in scleroderma, among others.</p> <p>In addition to these drug trials, we also maintain ongoing participation in the nationwide Canadian Scleroderma Research Group (CSRG) registry and the lupus registry "The 1000 Faces of Lupus", which involves monitoring the demographics and disease activity of these patients in our area. We are participating in the 3-year ThromboFIL study, which tracks thrombotic events in lupus sufferers, as well as other ongoing CSRG projects such as the development of classification criteria for scleroderma.</p>

Key publications (maximum 5 publications)

1. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, Smith CD, Chalmers IM, Hong P, O'Hanlon D, Kaminska E, Markland J, Sibley J, Catoggio L, Furst DE. A randomized controlled trial of Methotrexate versus placebo in early diffuse scleroderma. *Arthritis Rheum* 2001;44:1351-8.
2. Pope JE, Prashker M, Anderson J. The efficacy and cost-effectiveness of N of 1 studies with diclofenac compared to standard treatment with nonsteroidal anti-inflammatory drugs in osteoarthritis. *J Rheumatol* 2004;31(1):140-9.
3. Korn JH, Mayes M, Cerinic M, Rainisio M, Pope J, et al, for the RAPIDS-1 Study Group. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. *Arthritis Rheum* 2004;50(12):3985-93.
4. Thompson AE, Pope JE. Calcium Channel Blockers for Primary Raynaud's Phenomenon: A Meta-Analysis. *Rheumatology(Oxford)*. 2005 Feb; 44: 145-150.